NCT05155709 - A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

April 17, 2024

Study Completion Date

April 17, 2024

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

siremadlin

Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths

DRUG

venetoclax

Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.

DRUG

azacitidine

Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice

Trial Locations (10)

35340

Novartis Investigative Site, Izmir

40138

Novartis Investigative Site, Bologna

68000

Novartis Investigative Site, Kuala Selangor

78246

Texas Oncology Sammons Cancer Center, Dallas

97239

Oregon Health Sciences University, Portland

8457108

Novartis Investigative Site, Beersheba

9112001

Novartis Investigative Site, Jerusalem

Unknown

Novartis Investigative Site, Hong Kong

H-1083

Novartis Investigative Site, Budapest

05460

Novartis Investigative Site, Alor Star